Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Selling, General & Administrative
Antengene Corporation Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Selling, General & Administrative
-¥340.8m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Selling, General & Administrative
-¥4.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Selling, General & Administrative
-¥1.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Selling, General & Administrative
-¥10.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Selling, General & Administrative
-¥6.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Selling, General & Administrative
-¥233.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Selling, General & Administrative?
Selling, General & Administrative
-340.8m
CNY
Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Selling, General & Administrative amounts to -340.8m CNY.
What is Antengene Corporation Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-69%
Over the last year, the Selling, General & Administrative growth was 35%. The average annual Selling, General & Administrative growth rates for Antengene Corporation Ltd have been -30% over the past three years , -69% over the past five years .
You don't have any saved screeners yet